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Abstract: The Wnt signalling pathway is involved in regulating cellular proliferation and differentiation, and aberrant 
activation has been described in several cancers including breast. Oestradiol up regulates Wnt pathway gene 
expression, and thereby activates the Wnt signalling pathway. We used the oestrogen-responsive breast cancer cell line 
MCF-7 to examine the effects of secreted frizzled related protein 4 (sFRP-4) on oestradiol-induced growth, including 
gene expression of the Wnt signalling pathway genes Frizzled Receptor, Wnt-10b, and -catenin. We demonstrate here 
that sFRP-4 inhibits oestradiol-induced cell growth in the MCF-7 cell line and also down regulates oestradiol-induced 
expression of selected Wnt signalling genes including -catenin. We propose that sFRP-4 is a potent inhibitor of the Wnt 
signalling pathway and may negatively regulate oestradiol-mediated proliferation in human breast cancer cells.  
Keywords: Breast cancer, sFRP4, Wnt signalling, oestradiol, -catenin, cellular proliferation, growth inhibition. 
INTRODUCTION 
Reproductive tissues undergo cycles of hormone 
driven growth followed by regression involving 
apoptosis. A novel clone expressed in the rat corpus 
luteum undergoing regression was isolated by our 
laboratory [1, 2] and this gene, termed secreted 
Frizzled Related Protein-4 (sFRP-4), was shown by 
Northern blot analysis and in situ hybridization to be 
highly expressed in regressing ovarian, mammary 
gland, and ventral prostate tissues after hormone 
withdrawal [2]. sFRP-4 expression is undetectable in 
the resting mammary gland of the rat until involution, 
when there is a greater than ten-fold increase in sFRP-
4 expression [2].  
sFRP-4 is related to the frizzled (FZ) family, which 
functions as a receptor for the ubiquitous family of 
secreted Wnt signalling molecules. Based on amino 
acid sequence analysis, the FRP cDNA is believed to 
encode for the frizzled-like, cysteine-rich domain but 
not the seven-pass transmembrane domain seen in 
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other FZ family members [3]. Thus, it has been 
proposed the FRPs are secreted proteins that compete 
for Wnt ligand binding, as well as forming a dominant 
negative interaction with the FZ receptor to modulate 
the Wnt-frizzled signal transduction pathway [4].  
Northern blot analysis of a variety of human tissue 
RNA samples has shown that there are high levels of 
expression of sFRP-4 in ovary, prostate, testis, spleen, 
and thymus, but not in the colon, small intestine, and 
peripheral blood leukocytes. To date, only one 
published study has examined sFRP-4 expression in 
human breast tissue and breast tumours using in situ 
hybridization [5]. They identified an up regulation of 
sFRP-4 mRNA in in situ and invasive ductal breast 
carcinomas compared with the normal breast 
parenchyma [5]. The induction of sFRP-4 expression in 
the in situ carcinoma, the earliest form of breast 
tumour, suggests its expression may be an early 
neoplastic event [5]. Oestrogen has been implicated as 
a potential regulating factor of sFRP-4 due to the 
predominant expression of sFRP-4 during the 
oestrogenic phase of the endometrial cycle [5].  
SFRP-4 expression has been demonstrated in 
prostate carcinomas compared with normal prostate 
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tissue [6]. Membranous expression of sFRP-4 was 
associated with good patient prognosis, highlighting its 
potential as a prognostic marker and suggesting that 
sFRP-4 may be involved in counteracting unregulated 
growth in hormone-responsive cancers [6]. More 
recently, sFRP4 expression was associated with a 
better prognosis in ovarian cancer patients and acts 
through inhibition of the Wnt signalling pathway [7, 8]. It 
was found that over expressing sFRP4 in breast cancer 
cell lines that were resistant to cisplatin rendered these 
cells sensitive to treatment [7]. Furthermore, there was 
a positive association between decreased sFRP4 
expression and increased severity of tumour seen in 
patient tissue microarrays [7]. In the present study we 
examined the role of sFRP-4 on the growth of the 
breast cancer cell line MCF-7, specifically examining 
whether it was able to modulate oestradiol-induced cell 
growth.  
MATERIALS AND METHODS 
Cell Culture 
The human breast cancer cell line, MCF-7 (donated 
by Dr Jacky Bentel), was grown in RPMI 1640 (Gibco) 
supplemented with 10% foetal bovine serum (FBS) 
(JRH Biosciences), 2mM L-glutamine (L-glut) (Gibco), 
2mM penicillin (Gibco), and 2mM streptomycin (Gibco). 
Cells were cultured at 37°C with 5% CO2. Trypsinised 
MCF-7 cells were seeded onto 6-well tissue culture 
plates (Sarstedt) at a final concentration of 5 x 10
4
 cells 
per well for all experiments. Cells were incubated 
overnight to allow attachment to the well surface. 
Seeding day was allocated as day one. 
Oestradiol Treatment 
Phenol red-free (PRF) RPMI medium (Gibco) 
supplemented with 5% charcoal-stripped serum 
(Trace), 2mM L-glutamine (L-glut), 2mM of penicillin 
and streptomycin were added to the cells on day two to 
starve the cells of oestrogens. 100nM of 17 -oestradiol 
(E2) (Sigma) were added to the cells on day four 
together with fresh PRF charcoal-stripped growth 
medium. Cells were incubated with E2 for 72 hours.  
sFRP-4 Conditioned Media Experiments 
NIH:3T3 cells (derived from embryonic mouse 
fibroblasts and obtained from ATCC, Virginia, USA) 
were virally transfected with the sFRP-4 gene as 
previously described (Lacher et al. 2003). 3T3 cells 
were maintained in RPMI 1640 supplemented with 10% 
FBS, 2mM L-glut, 2mM penicillin, and 2mM 
streptomycin. The sFRP-4 conditioned media were 
aspirated and used in the sFRP4 treatment 
experiments. SFRP-4 protein concentration in the 
conditioned media was determined using a standard 
Bradford assay. Cell media were aspirated from 
untransfected 3T3 cells to use as a control for sFRP-4 
treatment. 
Determining sFRP-4 Dose 
Protein isolation was performed on the sFRP-4 
transfected (NIH:3T3+sFRP-4) and untransfected 3T3 
cell media to determine the total protein concentration 
of the media and, thus, approximate a dose of total 
protein for conditioned media treatment.  
10
6
 NIH:3T3 and NIH:3T3+sFRP-4 cells were 
seeded in separate T-25 culture flasks in RPMI, 10%, 
FBS, and 2mM penicillin and streptomycin antibiotics 
and left to adapt to the culture flask overnight. To 
ensure the conditioned media for treatment were not 
dominated by the proteins present in FBS, media were 
replaced with serum-free media and the cells cultured 
for 72 hours. Protein was extracted from the media 
following three days of culture. Medium was passed 
through a 0.45μm filter and two 3ml aliquots of each 
sample were transferred to 15ml falcon tubes. The 
unused media were stored at 4°C for future treatments. 
12ml of ice-cold acetone were added to each of media 
samples, the samples vortexed and then incubated at -
20°C for 60 minutes. Samples were then centrifuged at 
maximum speed at 4°C for 10 minutes to pellet the 
protein precipitate. The supernatant was removed and 
discarded and the acetone evaporated from the 
samples by leaving the tubes open at room 
temperature for 30 minutes. The protein pellet was then 
re-suspended in 50μl of 0.01X PBS, the two samples 
pooled together, and an aliquot set aside for the 
Bradford protein assay to determine total protein 
concentration. 
A 350μl dose of conditioned media from both 
transfected and untransfected cells was used for MCF-
7 treatment. The protein concentration of media 
samples was determined by Bradford protein assay, 
and this dose represents approximately 1.3mg of total 
protein for untransfected cell media and 1.6mg for 
3T3+sFRP-4 cell medium. The 300μg difference 
between these two samples potentially represents the 
amount of sFRP-4 present in the 3T3+sFRP-4 culture 
medium. The volume of conditioned media was kept 
constant for the MCF-7 treatments to control for the 
presence of depleted media in culture.  
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sFRP-4 Treatment 
PRF RPMI medium supplemented with 5% charcoal 
stripped serum, 2mM L-glutamine, 2mM penicillin and 
streptomycin was added to the MCF-7 cells on day two. 
350μl of sFRP-4 conditioned media were added to the 
treatment cells on day four together with 2mls of fresh 
PRF charcoal stripped growth medium. 350μl of 3T3 
untransfected cell media were added to the control 
cells together with 2mls of fresh PRF charcoal stripped 
media, to account for the addition of depleted growth 
media on the cells. Cells were incubated with sFRP-4 
for 72 hours.  
Combined Oestradiol and sFRP-4 Treatment 
A combined E2 and sFRP-4 treatment was 
undertaken to investigate whether sFRP-4 can 
counteract oestradiol-induced proliferation of MCF-7 
cells. These were performed in substantially the same 
way as described above except 350μl of sFRP-4, 
conditioned media were added to the cells on day four 
together with 2mls of fresh PRF charcoal stripped 
growth medium and 100nM E2, and then incubated for 
72 hours. Controls received 350μl of 3T3 untransfected 
cell media together with 2mls of fresh PRF charcoal 
stripped media and 100nM E2.  
Cell Proliferation Assay 
Following the 72 hour treatments of E2, sFRP-4 
conditioned media, and combined E2 and sFRP-4 
conditioned media, cells were trypsinised and counted 
using a haemocytometer (Nebauer Improved, Crown 
Scientific). To ensure accurate counting, each sample 
(n=3 for each sample) was loaded into the 
haemocytometer twice, and in each load, three 
representative 25-square areas were counted, resulting 
in six counts per sample.  
Real-Time RT-PCR 
RNA was extracted from MCF-7 cells using TRI 
REAGENT according to the manufacturer’s instructions 
(Molecular Research Centre). RNA concentration was 
determined from the absorbance at 260nm. 1μg of 
each RNA sample was DNase-treated using the DNA-
free™ kit (Ambion) according to manufacturer’s 
protocol to remove any genomic DNA contamination. 
RNA was reverse transcribed into cDNA, using M-MLV 
reverse transcriptase (Promega) according to a 
standard protocol. Point mutant #M3682 (Promega) 
was added to each sample. Clean-up for the reverse 
transcription reaction samples was completed using the 
Ultraclean PCR Clean-up DNA purification kit (MO BIO) 
in accordance with manufacturer’s protocol.  
The real-time PCR reaction mix consisted of 5μl of 
iQ™ SYBR
® 
Green Supermix (BIORAD), 1μl each 
forward and reverse primers (5μM) (table 2.1), 2μl of 
dH2O, and 1μl of cDNA to make a total reaction volume 
of 10μl. 1μl of water was added instead of cDNA in 
negative (no-template) controls. Samples were 
measured in duplicates. The PCR reaction was 
performed on a Rotor-Gene RG-3000 (Corbett 
Research). Cycling conditions varied for each gene and 
are detailed in Table 1. A fluorescence measure was 
taken at the end of each cycle to form an amplification 
curve. The starting amount of cDNA template was 
extrapolated from Ct values and was the basis for 
calculating and comparing mRNA expression for each 
sample. Quantitation values were normalized to the 
housekeeping gene L-19, determined by the 
absorbance reading at 260nm. Amplified product 
obtained from the PCR reaction was run on a 2% 
agarose gel to determine product size.  
Immunoblotting 
Protein was extracted from MCF-7 cells by 
incubating with 100μl of RIPA buffer for 30 min on ice. 
The samples were centrifuged at maximum speed for 5 
minutes at 4°C. The concentration of the protein 
supernatant was determined by BSA assay. 50μg of 
protein were separated by SDS gel electrophoresis on 
a 10% polyacrylamide gel, and then transferred onto a 
Hybond™-C nitrocellulose membrane (Amersham). 
Membranes were blocked in 0.5% (v/w) gelatin solution 
for 30 minutes at 37°C. To detect sFRP-4 protein 
expression, rabbit polyclonal anti-rat sFRP-4 (Upstate 
Biotechnology, USA) was applied to the membranes. 
The human and rat proteins share 90% homology 
(Pubmed library: rat: NP_445996, human: 
NP_003005). The sFRP-4 antibody was diluted 1:250 
in TBST-0.05% and incubated with the membrane 
overnight at 4°C with shaking. Membranes were then 
incubated with HRP-conjugated goat anti-rabbit IgG 
(DAKO) diluted 1:5000 for 1 h at room temperature. All 
signals were detected using enhanced 
chemiluminescence system (SuperSignal
®
 West Pico 
Chemiluminescent substrate PIERCE).  
The activity of the Wnt signalling pathway was 
measured by quantifying the levels of 
dephosphorylated -catenin. Mouse anti-active -
catenin antibody (Upstate™) was diluted 1:330 in 
TBST-0.05% and incubated with the membrane 
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overnight at 4°C with shaking. Membranes were then 
incubated with HRP-conjugated rabbit anti-mouse IgG 
(DAKO) diluted 1:5000 for 1 h at room temperature.  
Membranes were stripped of antibody by incubating 
with stripping buffer for 30 minutes at room 
temperature, and then re-probed with the house-
keeping protein -actin. The membranes were blocked 
in skim milk powder for 30 min at 37°C followed by 
incubation with the -actin antibody (Sigma) (1:5000) 
overnight at 4°C with shaking. Membranes were then 
incubated with secondary HRP-conjugated rabbit anti-
mouse IgG (1:10000) for 1 h at room temperature.  
Western blots were quantified using Scion Image 
software by analysing the pixel density between the 
control and treatment samples. Data were normalised 
by dividing quantitation values by the -actin 
quantitation values to account for any error in loading 
or variation in protein concentration.  
Statistical Analysis 
Data are represented as mean values ±SEM. 
Differences between groups were analysed by an un-
paired two-tailed t-test with equal variances, and were 
considered statistically significant when p<0.05. 
RESULTS 
We used a cell counting method to establish 
proliferation rates of MCF-7 cells grown in culture. 
When MCF-7 cells were treated with 17 -oestradiol for 
a 72 hour period, we observed a 25% increase in cell 
number compared to the ethanol control (p<0.001; 
Figure 1A). When MCF-7 cells were incubated with 
sFRP-4 alone, there was a statistically significant but 
relatively modest 15% reduction in MCF-7 cell number 
by comparison with untreated cells (p=0.003; Figure 
1B). Finally, when sFRP-4 was added in combination 
with oestradiol, we observed that the increase in the 
number of cells we might have expected was reduced 
about one half when compared to oestradiol treatment 
alone (p<0.001; Figure 1C). Taken together, these 
results suggest sFRP-4 antagonises MCF-7 cell 
proliferation both with and without oestradiol driving 
that growth.  
To ensure that oestradiol was not affecting 
endogenous sFRP-4 levels, we examined both mRNA 
and protein expression of sFRP-4 in MCF-7 cells for all 
treatments. No statistical difference was observed 
between either endogenous sFRP-4 mRNA or protein 
levels in any of our experiments (Figure 2).  
Since oestradiol has been previously described as 
stimulating expression of Wnt pathway associated 
genes in MCF-7 cells, and we had observed that sFRP-
4 could suppress oestradiol-induced cellular 
proliferation, we undertook to quantitate expression of 
these genes to determine if sFRP-4 was suppressing 
their expression. We selected Wnt-10b for RT-PCR 
analysis because this has been previously associated 
with oestradiol-induced Wnt pathway stimulation [9-11]. 
All treatments were for 72 hours and, in all PCR 
Table 1: Gene Primers and Thermocycling Conditions for Genes Examined 
Gene Primer Sequence Cycling conditions Cycles Product Size 
sFRP-4 F 5’ TCT GTA CCA AAG GGC AAA 3’ 
R 5’ACC ACC GTT GTG ACC TCA TT 3’ 
94°C for 3mins 
94°C for 30sec 
60°C for 30sec 
72°C for 30sec 
45 110bp 
Fz-4 F 5’ GAC AAC TTT CAC ACC GCT CA 3’ 
R 5’ GGC AAA TCC AAA TTC CTT CA 3’ 
94°C for 3mins 
94°C for 30sec 
55°C for 30sec 
72°C for 30sec 
45 178 bp 
Wnt-10b F 5’ TGG GCC GGG CCA TCT TCA TT 3’ 
R 5’GGC TGC CAC AGC CAT CCA AC 3’ 
94°C for 3mins 
94°C for 30sec 
60°C for 30sec 
72°C for 60sec 
45 204 bp 
-catenin F 5’ GAT TTG ATG GAG TTG GAC 3’ 
R 5’ TGT TCT TGA GTG AAG GAC 3’ 
94°C for 3mins 
94°C for 30sec 
52°C for 30sec 
72°C for 30sec 
45 218 bp 




















































































Figure 1: MCF-7 cell counts following 72hrs of treatment. 
(A) Cells treated with E2 for showed a 25% increase in cell number compared to controls (*p<0.001). (B) Exogenous sFRP-4 
treatment resulted in a 15% reduction in MCF-7 cell number (**p=0.003). (C) Combined treatment of E2 and sFRP-4 resulted in a 
50% reduction in MCF-7 cell number (***p<0.001). Values indicate the average total number of cells as determined by 
haemocytometer counts ± SEM. A two-tailed t-test confirmed statistical significance between the two treatment groups (n=4 per 
treatment group). 
 
      (A)    (B) 
 
(C) 
Figure 2: Effect of 72hrs of oestradiol treatment on endogenous sFRP4 mRNA and protein levels. 
(A) Lane one is a 100 base pair ladder, arrow indicates 500kb, bands decrease in 100bp increments. Lane two represents 
control (C) and E2 treatment (T) sFRP-4 PCR product 110bp in length (dissected from the gel). (B) Western blot demonstrating 
control (C) and E2 treatment (T) bands of sFRP-4 protein. sFRP-4 antibody detected a 40kDa protein and 55kDa glycosylated 
sFRP-4 protein and -actin (dissected from the gel). (C) Quantitation by densitometry, followed by normalisation to -actin 
protein expression showing no change in sFRP4 protein levels (n=4).  







Figure 3: Quantitation graph of Wnt signalling genes following treatments.  
Values represent the mean relative mRNA expression averaged from four samples ± SEM as determined by comparative 
quantitation analysis. Values were normalised to the housekeeping gene L-19. Asterisks denote significance as determined by a 
two-tailed t-test. (A) Quantitation graph of -catenin, Wnt-10b, and FZ-4 mRNA following E2 treatment for 72hrs. Treatment 
resulted in a significant increase in the mRNA of all three genes (p<0.001 for all genes). (B) Quantitation of Wnt signalling genes 
following exogenous sFRP-4 treatment for 72hrs. Treatment caused a significant reduction in both -catenin and FZ-4 mRNA 
(p=0.005, p=0.039 respectively). (C) Quantitation of Wnt signalling genes following 72hrs of combined E2 and sFRP-4 treatment. 
A significant reduction in -catenin was apparent following combined treatment (p=0.001). The graphical data represent the 
mean values ±SEM of treatment groups (n=4). 
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reactions, a single peak was detected on the melt 
curve indicating the amplification of a single PCR 
product. Negative controls did not show product 
amplification (data not shown).  
E2 Treatment 
Oestradiol treatment resulted in a highly significant 
four-fold increase in Wnt-10b mRNA, a 3 fold increase 
in -catenin mRNA, and a 2.7 fold increase in FZ-4 
mRNA levels by comparison with control (p<0.001, 
Figure 3A). 
A reduction in the levels of Wnt-10b mRNA showed 
a trend towards significance (p=0.06; Figure 3B). 
SFRP-4 treatment resulted in a 50% reduction in -
catenin mRNA levels (p=0.002) and also induced a 
statistically significant 70% reduction in FZ-4 mRNA 
levels by comparison with control (p=0.03; Figure 3B). 
The combined treatment resulted in suppression of 
the oestradiol-induced expression of Wnt-10b and FZ-
4, but this was not statistically significant for either Wnt-
10b or FZ-4 (p=0.8, p=0.1 respectively; Figure 3C). 
However, a significant reduction in -catenin mRNA 
levels was detected in treated cells (p=0.01). 
Whilst we had demonstrated a suppression of 
expression of both ligand and receptor of Wnt 
signalling pathway genes by sFRP-4 in MCF-7 cells, it 
was not clear if this actually resulted in a suppression 
of Wnt signalling itself. Therefore we investigated this 
by using an antibody that is specific to the active 
dephosphorylated form of -catenin. A 92kDa protein 
band was detected in both control and treated protein 
samples, and was not detected in no-primary antibody 
controls (Figure 4). Exogenous sFRP-4 treatment 
resulted in a highly significant halving of the levels of 
active -catenin protein in MCF-7 cells (p=0.01; Figure 
4A), indicating a suppression of the Wnt signalling 
pathway. A slight, non-significant increase in active -
catenin protein levels followed combined E2 and sFRP-
4 oestradiol treatment (p=0.77; Figure 4B).  
DISCUSSION 
Oestradiol is able to induce proliferation in the 
breast cancer cell line MCF-7, and there is evidence 
that this is mediated through the Estrogen Receptor 
(ER) acting as a transcription factor controlling the up 
regulation of genes involved in progression through the 
cell cycle, such as c-myc and cyclin D1 [12]. Oestradiol 
also results in the up regulation of selected Wnt genes 
[13-19], although whether these are under the direct 
control of the ER has not been demonstrated since the 
promoter region of these genes does not have 
Estrogen Response Element sequences.  
In prostate cancer cells, sFRP-4 was associated 
with a better prognosis and, in in vitro experiments, 
    
    (A)        (B) 
Figure 4: (A) Active -catenin protein levels were measured following 72hrs of sFRP-4 treatment to determine its effect on Wnt 
signalling activity. Western blot demonstrating control (C) and treatment (T) band of 92kDa active -catenin and -actin 
(dissected from the gel). Quantitation by densitometry, followed by normalisation to -actin protein expression, demonstrated a 
55% reduction in the levels of active -catenin protein compared to the control following sFRP-4 treatment (*p=0.01; two-tailed 
t-test). (B) Active -catenin protein levels were determined following 72hrs of combined E2 and sFRP-4 treatment. Western blot 
demonstrating control (C) and treatment (T) band of 92kDa active -catenin and -actin (dissected from the gel). Analysis 
revealed no significant difference between the levels of active -catenin protein in control or combined treated cells (p=0.77). 
The graphical data represent the mean values ±SEM of treatment groups (n=4). 
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over expression of the sFRP-4 protein was able to 
down regulate the canonical Wnt signalling pathway 
[6]. Wnt-mediated signalling leads to an increase in the 
active form of cytosolic -catenin, which in turn 
translocates to the nucleus where it is involved in co-
receptor activity with T-cell factor/Lymphoid enhancer 
factor (TCF/LEF) transcription factors [18]. This 
pathway is also associated with enhancing the 
transcription of Wnt target genes such as c-myc and 
cyclin D1 [19]. 
Previous studies have demonstrated that 
transcription of some Wnt genes is induced by 
oestradiol in MCF-7 cells [11, 13, 14, 16, 17]. However, 
none of these studies demonstrated whether this up 
regulation led to an increase in Wnt signalling activity 
or in cell proliferation. In the present study, oestradiol 
was able to stimulate proliferation in MCF-7 cells and 
also increase the expression of selected Wnt signalling 
pathway genes. We chose Wnt-10b as a candidate 
Wnt gene as it has been previously reported to be up 
regulated following oestradiol treatment [11], and has 
been implicated in human breast cancer [9]. We also 
examined the expression of FZ-4 since we have 
previously shown it to interact with sFRP4 in the rodent 
ovary [20]. RT-PCR analysis demonstrated a significant 
oestradiol-induced increase in the expression of Wnt-
10b (p<0.001), consistent with previous data [11]. In 
addition, we observed an increase in the expression of 
mRNA for the Wnt receptor FZ-4 as well as an increase 
in the downstream Wnt signalling marker -catenin 
(p<0.001 for both genes), suggesting that oestradiol 
was associated with activation of the Wnt signalling 
pathway in MCF-7 cells. However, we did not observe 
an increase in the active form of the -catenin protein, 
in contradiction of the mRNA expression seen following 
oestradiol treatment (data not shown). These results 
seem to suggest that either oestradiol modulates the 
expression of active- -catenin to steady-state levels, or 
that oestradiol induces MCF-7 proliferation by a 
mechanism independent of the Wnt signalling pathway. 
Alternatively, active- -catenin levels may be increasing 
at a later time point, which may then act to increase cell 
proliferation but alternative oestrogen signalling 
pathways are able to induce proliferation earlier. 
Oestradiol is known to regulate the expression of 
genes involved in cell-cycle progression such as c-myc 
and cyclin [12]. It is likely that oestradiol induced MCF-
7 cell proliferation is brought about by up-regulating the 
expression of these cell-cycle genes and that the Wnt 
signalling pathway is either activated at a later time-
point, or is not regulated by oestradiol and plays no 
part in oestrogen-induced cellular proliferation in MCF-
7 cells. In support of the antagonistic role of sFRP-4 to 
oestrogen-driven cell proliferation, it has recently been 
shown that sFRP-4 is able to down regulate the 
expression of c-myc and cyclin D1 [21]. 
As predicted, exogenous sFRP-4 treatment 
significantly reduced MCF-7 cell proliferation, both 
under normal growth conditions and when stimulated 
by oestradiol. When treated with sFRP-4 alone, we 
observed a decrease in cell proliferation and this was 
associated with a decrease in both the levels of mRNA 
and the active form of the -catenin protein. This 
observation is consistent with the proposed model of 
sFRP-4 antagonism of the Wnt signalling pathway, 
whereby its binding to Wnt prevents an association with 
the FZ receptor or formation of a non-functional 
complex with the FZ receptor [4, 6, 22]. This implies 
that, in untreated MCF-7 cells, normal cell growth 
requires an active Wnt signalling pathway or that this 
pathway is able to interfere with normal growth. Figure 
5A represents a proposed model of the interaction 
between sFRP-4 and oestradiol on the MCF-7 breast 
cancer cell line. 
 
Figure 5: Oestradiol increases MCF-7 cellular proliferation 
and the expression of Wnt-10b, FZ-4, and -catenin at the 
gene level. However, sFRP-4 is able to block these 
oestradiol-induced effects. 
When oestradiol and sFRP-4 were combined there 
was a significant reduction in the anticipated effect of 
oestradiol-induced cell growth in the MCF-7 cells. As 
there was no significant increase in active -catenin 
protein due to oestradiol treatment alone, it was 
anticipated that when sFRP-4 was combined with 
oestradiol, it should still reduce the amount of -
catenin, as had been seen with sFRP-4 treatment 
alone; and this would be consistent with sFRP-4 acting 
through the Wnt signalling pathway. However, this was 
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not the case. It is possible that, because the Wnt 
signalling pathway results in transcriptional regulation 
of genes that are also transcriptionally activated by 
oestradiol, there is some overlap of these two 
pathways. That is, when sFRP-4 down regulates the 
Wnt pathway, the consequent absence of the TCF/LEF 
transcription factors results in a less potent response to 
oestradiol-induced gene expression of cell cycle 
regulatory genes. This then diminishes oestradiol-
induced cell growth.  
No change was detected in sFRP-4 mRNA or 
protein in any of the treatments, suggesting that 
oestradiol itself does not regulate the expression of 
sFRP-4 in the MCF-7 cell line. It is not presently known 
what does increase sFRP-4 expression in normal cells, 
although it has been associated with apoptosis [23]. 
More recently, silencing of sFRP-4 via promoter 
methylation has been demonstrated in -catenin 
deficient mesothelioma cell lines [23]. Re-expression of 
sFRP-4 in these cells has been shown to not only block 
Wnt signalling, but to induce apoptosis as well as 
suppress cell growth [24]; further supporting a growth 
suppressant and apoptotic role for sFRP-4.  
Membranous sFRP-4 expression in prostate cancer 
has been shown to be predictive of good prognosis, 
and transfection of sFRP-4 into prostate cancer cells 
reduces cell proliferation [6]. Our data indicate that 
sFRP-4 is able to suppress the growth of breast cancer 
cells and that it may also suppress oestradiol-
stimulated growth. It would be valuable to determine 
sFRP-4 expression in a cohort of breast cancer 
samples, together with other known markers such as 
Estrogen Receptor status, to ascertain whether sFRP-4 
is also associated with a favourable prognosis in breast 
cancer.  
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